Markers and tissue resources for melanoma: Meeting report

Cancer Research

Volumn 66, Issue 22, 2006, Pages 10652-10657

  Becker, Dorothea ^a   Mihm, Martin C ^b   Hewitt, Stephen M ^d   Sondak, Vernon K ^c   Fountain, Jane W ^d   Thurin, Magdalena ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; ALPHA INTERFERON; ALPHA UPSILON BETA 3 INTEGRIN; CARBOPLATIN; CELL ADHESION MOLECULE; DACARBAZINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; SORAFENIB; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER TISSUE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MEGADOSE; DRUG TARGETING; HUMAN; MELANOMA; METASTASIS; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

HUMANS; MELANOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 33845329568     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0921     Document Type: Conference Paper

References (43)

1. American Cancer Society. ACS cancer facts and figures. Atlanta (GA): American Cancer Society, Inc.; 2005.
2. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
3. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985;35:130-51.
4. Cook MG, Spatz A, Brocker EB, Ruiter DJ. Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J Pathol 2002;197:188-93.
5. Giuliano AE, Cochran AJ, Morton DL. Melanoma from unknown primary site and amelanotic melanoma. Semin Oncol 1982;9:442-7.
6. Breslow A. Thickness, cross-sectional areas, and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
7. Slingluff CL, Jr., Seigler HF. "Thin" malignant melanoma: risk factors and clinical management. Ann Plast Surg 1992;28:89-94.
8. Bedrosian I, Faries MB, Guerry D, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 2000;7:262-7.
9. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004;22:2671-80.
10. Johnson TM, Sondak VK. Melanoma margins: the importance and need for more evidence-based trials. Arch Dermatol 2004;140:1148-50.
11. Chamberlain AJ, Fritschi L, Kelly JW. Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection. J Am Acad Dermatol 2003;48:694-701.
12. Elder DE, Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology 2004;36:428-34.
13. Martinez SR, Hoon DS. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony? J Cell Biochem 2005;96:473-83.
14. Kononen J, Bubendorf L, Kallioniemi O, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
15. Pacifico MD, Grover R, Richman P, Daley F, Wilson GD. Validation of tissue microarray for the immunohistochemical profiling of melanoma. Melanoma Res 2004;14:39-42.
16. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003;63:8103-7.
17. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 2005;115:367-75.
18. Carlson JA, Ross JS, Slominski A, et al. Molecular diagnostics in melanoma. J Am Acad Dermatol 2005;52:743-75.
19. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
20. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005;102:6092-7.
21. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 2005;4:1018-29.
22. Wang E, Panelli MC, Zavaglia K, et al. Melanoma-restricted genes. J Transl Med 2004;2:1-34.
23. Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62:3581-6.
24. Alonso SK, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004;164:193-203.
25. 1 integrin expression in metastatic melanoma. Melanoma Res 2000;10:243-51.
26. 3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene 2005;24:4710-20.
27. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003;22:6524-36.
28. Zhuang L, Lee CS, Scolyer RA, et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 2005;58:1163-9.
29. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006;79:639-51.
30. Morales J, Homey B, Vicari AP, et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci U S A 1999;96:14470-5.
31. Duncan LM, Deeds J, Cronin FE, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 2001;19:568-76.
32. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951-60.
33. Bosserhoff AK, Hein R, Bogdahn U, Buettner R. Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 1996;271:490-5.
34. Leslie MC, Bar-Eli M. Regulation of gene expression in melanoma: new approaches for treatment. J Cell Biochem 2005;94:25-38.
35. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21.
36. Zhou Y, Dai DL, Martinka M, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005;124:1044-52.
37. +CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
38. Rhodes A. Quality assurance in immunohistochemistry. Am J Surg Pathol 2003;27:1284-5.
39. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-7.
40. 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Clin Oncol 2005;23:Abstract 7507.
41. Flaherty KT, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C), and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 2004;22:Abstract 7507.
42. King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, Fisher DE. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for Melanoma Diagnosis. Am J Pathol 1999;155:731-8.
43. Mills L, Tellez C, Huang S, et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002;62: 5106-14.